Characterization and Assessment of Cold Plasma for Cancer Treatment

作     者：Shakya, Aavash Pradhan, Suman Prakash Basnet, Niroj Shrestha, Rajendra Joshi, Pusp Raj Gautam, Roshan Paneru, Aakash Ashok, G.C. Shah, Arun Kumar Adhikari, Rameshwar Subedi, Deepak Prasad Regmi, Sagar 

作者机构：Department of Physics School of Science Kathmandu University Dhulikhel Nepal Department of Environmental Science and Engineering School of Science Kathmandu University Dhulikhel Nepal Department of Physics Nepal Banepa Polytechnic Institute Kavre Banepa Nepal Department of Physics Tribhuvan University Patan Multiple Campus Lalitpur Nepal Annapurna Research Center Kathmandu Nepal School of Computing and Digital Technology Birmingham City University United Kingdom Department of Chemical Science and Engineering School of Engineering Kathmandu University Dhulikhel Nepal Research Centre for Applied Science and Technology Tribhuvan University Kathmandu Nepal Nepal Academy of Science and Technology Lalitpur Nepal Department of Pharmacology School of Medicine Case Western Reserve University ClevelandOH44106 United States 

出 版 物：《Plasma Medicine》 (Plasma Med.)

年 卷 期：2022年第12卷第2期

页      面：1-14页

核心收录：

学科分类：0808[工学-电气工程] 0809[工学-电子科学与技术（可授工学、理学学位）] 070204[理学-等离子体物理] 0710[理学-生物学] 0831[工学-生物医学工程（可授工学、理学、医学学位）] 1007[医学-药学(可授医学、理学学位)] 100706[医学-药理学] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 0804[工学-仪器科学与技术] 0836[工学-生物工程] 0702[理学-物理学] 10[医学] 

基　　金：The authors acknowledge the University Grants Commission (UGC), Sanothimi, Bhaktapur, Nepal, for providing the Master Research Support (MRS-77/78-S&T-90). The authors would also like to thank the UGC for providing a postdoctoral fellowship to S.R. (UGC Award No. PF-76/77-S&T-01). The authors declare no competing interests. Author contributions were as follows. A.S.: Designed the work, acquired laboratory works, generated and analyzed data, and prepared the manuscript S.P.P.: Designed the work, analyzed the data, and prepared the manuscript N.B.: Analyzed the data and prepared the manuscript R.S.: Designed the work and prepared the manuscript P.R.J.: Conceived the study and the methodology for cytotoxicity studies, reviewed and edited the manuscript A.P.: Prepared the manuscript A.G.C.: analyzed the DPPH data A.K.S.: provided laboratory support R.A. and D.P.S.: supervised the project and S.R.: conceived the study, analyzed the data, prepared the manuscript, and supervised the project 

主　　题：Argon 

摘      要：The unbalanced lifestyle and rampant use of modern medicine are the lead-ing causes of life-threatening cancer disease prevalence. In the last few decades, chemotherapy and other medication techniques promised to cure cancer. However, cold plasma on cancer cell lines gets little attention due to a lack of understanding of the detailed mech-anism of action. In the contemporary time frame, it is well established that cold plasma therapy is one of the best alternatives for treating cancer. The selectivity of cancer cells by plasma treatment has a unique potential as therapeutics in future clinical practices. In this study, we analyzed the potential of cold atmospheric plasma (CAP) irradiated medium as a promising anti-cancer tool by using a high-voltage power source with a 20 kHz operat-ing frequency. The discharge was generated with argon as working gas and characterized by optical emission spectroscopy. Eagle’s minimum essential medium (EMEM) was treated with CAP utilizing argon as a plasma source at 2–3 kV for varied time durations (0 min, 1 min, 2 min, 3 min, 4 min, and 5 min) to demonstrate the anti-cancer capabilities of CAP treated media. The treated media culture grows cervical cancer cells (HeLa), breast cancer cells (MCF-7), mouse fibroblast cell line (3T3), and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay was carried out to determine the cell viability and inhibition rate. Our results revealed a considerable difference in viability between cancer cells and normal cells as treatment time increases from 1 to 5 min. The cell viability for HeLa (15.23%) and MCF-7 (16.18%) as compared to 3T3 cells (134.56%). This study provides evidence for the potential of CAP-treated media as an avenue for an anti-cancer representative. © 2022 by Begell House, Inc.